Topical Rapamycin Showed Promise for Lymphatic Malformations
New clinical data suggests a topical gel could offer a treatment option with lower systemic exposure for patients.
Updated on Oct. 12, 2026 in Diseases — General
Live Poll
Do you trust that pharmaceutical companies prioritize the development of treatments for rare, orphan skin diseases?
Palvella Therapeutics presented Phase 3 clinical data showing that its investigational topical rapamycin treatment improved symptoms in patients with microcystic lymphatic malformations. The results highlight a potential alternative to oral medications for those managing this condition.
Why it matters
This research is significant because it explores a targeted approach that minimizes the systemic drug levels often associated with oral sirolimus. By maintaining low and stable blood concentrations, this treatment could improve the balance between clinical efficacy and systemic safety for patients.
In a Phase 3 study, 95% of participants demonstrated improvement on the primary efficacy endpoint after a 24-week evaluation period. Additionally, pharmacokinetic analysis in 24 participants confirmed that systemic rapamycin exposure was at least 40-fold lower than that of oral sirolimus.
The players
Palvella Therapeutics
A biopharmaceutical company based in Wayne, Pa., focused on developing novel therapies for rare skin and lymphatic conditions.
The details
The investigational topical gel, known as QTORIN rapamycin, functions by delivering the active drug directly to the site of the lymphatic malformation. This localized application is designed to limit the amount of the drug that enters the bloodstream compared to oral versions. The study utilized embedded qualitative interviews to capture meaningful patient-reported improvements in symptoms throughout the 24-week treatment period.
Timeline
The analysis of DSAP patient claims covered the years 2018-2025.
Palvella Therapeutics completed the rolling New Drug Application submission in August 2026.
The company presented the study findings on October 12, 2026.
A Phase 2 trial for QTORIN pitavastatin is expected to start in the fourth quarter of 2026.
Health Landscape
These results from the SELVA clinical research program represent a shift toward localized drug delivery for complex lymphatic malformations. This approach follows the broader industry trend of re-engineering established systemic therapies into topical formats to reduce total body burden.
If you are managing a lymphatic malformation, it is worth discussing these emerging treatment developments with your specialist to understand how localized therapies might fit into your long-term care plan. Always coordinate with your physician before considering any new clinical trial or investigational medication.
The takeaway
The study suggests that localized treatment could offer symptomatic relief while significantly reducing systemic exposure to medications. Readers managing chronic skin or lymphatic conditions should track the progress of these trials and consult their dermatologist or specialist for updates on new therapy options.
What happens next
Palvella Therapeutics anticipates launching a Phase 2 trial for QTORIN pitavastatin during the fourth quarter of 2026.
Further reading
For more information on the management of chronic conditions, visit the Diseases — General section of our site.
Live Poll
Do you trust that pharmaceutical companies prioritize the development of treatments for rare, orphan skin diseases?
